

2017 (67)

Åpepek Teresa, Kwiatkowska Anna, Couture Frédéric, Ly Kévin, Desjardins Roxane, Dory Yves, Prah Adam, Day Robert. Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations. *Eur J Cell Biol.* 2017 Aug; 96 (5) 476-485-

Ahmed Musaddeque, Sallari Richard C, Guo Haiyang, Moore Jason H, He Housheng Hansen, Lupien Mathieu. Variant Set Enrichment: An R package to identify disease-associated functional genomic regions. *BioData Mining.* 2017; 10 9

Alfaro JA, Ignatchenko A, Ignatchenko V, Sinha A, Boutros PC, Kislinger T. Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines. *Genome Medicine.* 2017 July; 9 62

Altaylouni T, Zouanat F, Scarlata E, Benidir T, Hamel L, Brimo F, Begin L, Aprikian A, Chevalier S. The Androgen Receptor Becomes a Novel Predictive Biomarker of Prostate Cancer Progression When Post Translationally Activated by the Fer Kinase on Tyrosine 223. *Journal of Urology.* 2017 Apr; 197 (4) E1270-E1271

Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppala IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer. *European Urology.* 2017 July; 72 (1) 34-42

Ban FQ, Dalal K, Li HF, LeBlanc E, Rennie PS, Cherkasov A. Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action. *Journal of Chemical Information and Modeling.* 2017 May; 57 (5) 1018-1028

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang YZ, Beltran H, Zoubeidi A. The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer. *Cancer Discovery.* 2017 Jan; 7 (1) 54-71

Brett SI, Lucien F, Guo C, Williams KC, KY, Durfee PN, Brinker CJ, Chin JI, Yang J, Leong HS. Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples. *Prostate.* 2017 Sep; 77 (13) 1335-1343

Briollais L, Ozcelik H, Xu JX, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. *Journal of the National Cancer Institute.* 2017 Apr; 109 (4) djw258

Butler MS, Roshan-Moniri M, Hsing M, Lau D, KA, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo YB, Yamazaki T, Lawn S, Gleave ME, Gregory-Evans CY, McIntosh LP, Cox

ME, Rennie PS, Cherkasov A. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. *Oncotarget*. 2017 Jun; 8 (26) 42438-42454

Ceroici C, Zemp RJ. Large-Scale Nonlinear Lumped and Integrated Field Simulations of Top-Orthogonal-to-Bottom-Electrode CMUT Architectures. *IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control*. 2017 July; 64 (7) 1087-1091

Chen RQ, Yu Y, Dong XS. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer. *Journal of Steroid Biochemistry and Molecular Biology*. 2017 Feb; 166 91-96

Chevrier M, Bobbala D, Villalobos-Hernandez A, Khan MGM, Ramanathan S, Saucier C, Ferbeyre G, Geha S, Ilangumaran S. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. *BMC Cancer*. 2017 Feb; 17 157

Chin Lee C L, Cook Elina K, Yohan Darren, KAnthony, Niu Carolyn, Wilson Brian C, Liu Stanley K. Early biomarker for radiation-induced wounds: Day one post-irradiation assessment using hemoglobin concentration measured from diffuse optical reflectance spectroscopy. *Biomedical Optics Express*. 2017 Mar; 8 1682-1688

Cho CF, Yu L, Nsiama TK, Kadam AN, Raturi A, Shukla S, Amadei GA, Steinmetz NF, Luyt LG, Lewis JD. Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature. *Nanoscale*. 2017 Sep; 9 (33) 12096-12109

Cisneros L, Bussey KJ, Orr AJ, Miocevic M, Lineweaver CH, Davies P. Ancient genes establish stress-induced mutation as a hallmark of cancer. *PLoS One*. 2017 Apr; 12 (4) e0176258

Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Levesque E, Cancel-Tassin G. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. *World Journal of Urology*. 2017 Feb; 35 (2) 293-298

Cortes-Benitez F, Roy J, Maltais R, Poirier D. Impact of androstane A- and D-ring inversion on 17 β -hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability. *Bioorganic and Medicinal Chemistry*. 2017 Apr; 25 (7) 2065-2073

David M, Dursi LJ, Yao DL, Boutros PC, Simpson JT. Nanocall: An open source basecaller for Oxford Nanopore sequencing data. *Bioinformatics*. 2017 Jan; 33 (1) 49-55

Di Meo A, Batruch I, Yousef AG, Pasic MD, Diamandis EP, Yousef GM. An integrated proteomic and peptidomic assessment of the normal human urinome. *Clinical Chemistry and Laboratory Medicine*. 2017 Feb; 55 (2) 237-247

Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Patterson L, Dubin JA, Mourtzakis M. Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason

Scores in Prostate Cancer. *Prostate*. 2017 Feb; 77 (2) 211-221

Dianati V, Shamloo A, Kwiatkowska A, Desjardins R, Soldera A, Day R, Dory YL. Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3. *ChemMedChem*. 2017 Aug; 12 (15) 1169-1172

Donmez N, Malikić S, Wyatt AW, Gleave ME, Collins CC, Sahinalp SC. Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data. *Journal of Computational Biology*. 2017 Jun; 24 (6) 515-523

Dragomir A, Rocha J, Vanhuysse M, Kassouf W, Cury F, Hu J, Aprikian A. Treatment patterns and trends of patients dying of prostate cancer in Quebec: a population-based study. *Current Oncology*. 2017 May; 20 A124

Duivenvoorden WCM, Hopmans SN, Austin RC, Pinthus JH. Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. *Oncology Letters*. 2017 May; 13 (5) 3624-3630

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC. Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*. 2017 Jan; 541 (7637) 359-364

Ghiam AF, Vesprini D, Liu SK. Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer. *Translational Andrology and Urology*. 2017 Apr; 6 (2) 326-330

Hedden Lindsay, Wassersug Richard, Mahovlich Sarah, Pollock Phil, Sundar Monita, Bell Robert H, Goldenberg Larry, Higano Celestia S. Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners. *BJU International*. 2017 May

Hu Jason, Aprikian Armen G, Cury Fabio L, Vanhuysse Marie, Zakaria Ahmed S, Richard Patrick O, Perreault Sylvie, Dragomir Alice. Comparison of surgery and radiation as local treatment in the risk of loco-regional complications in men subsequently dying from prostate cancer. *Clinical Genitourinary Cancer*. 2017 Sep

Hua JJ, Lu J, Isaev K, Soares F, Guo HY, Ahmed M, He HH. Noncoding RNA for personalized prostate cancer treatment: utilizing the 'dark matters' of the genome. *Personalized Medicine*. 2017 Mar; 14 (2) 159-169

Huang KC, Evans A, Donnelly B, Bismar TA. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Pathology & Oncology Research. 2017 Apr; 23 (2) 399-407

Islam MF, Watanabe A, Wong L, Lazarou C, Vizeacoumar FS, Abuhussein O, Hill W, Uppalapati M, Geyer CR, Vizeacoumar FJ. Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens. *Scientific Reports*. 2017 Apr; 7 1040

Kalina J, Neilson D, Lin Y, Hamilton P, Comber A, Loy E, Sahinalp S, Collins C, Hach F, Lum J. Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer. *Clinical Cancer Research*. 2017 Sep

Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum JJ. Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. *Cancers*. 2017 Feb; 9 13

Kaur H, Siemens DR, Black A, Robb S, Barr S, Graham CH, Othman M. Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. *Canadian Urological Association Journal*. 2017 Feb; 11 33-38

Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K, Haegert A, Wyatt AW, Volik SV, Chi KN, Collins CC, Sahinalp C. SiNVICT: Ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. *Bioinformatics*. 2017 Jan; 33 (1) 26-34

Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, Shiah YJ, Fraser M, van der Kwast T, Boutros PC, Bristow RG, Lupien M. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. *Nature Genetics*. 2017 Sep; 49 (9) 1336

Lahr RM, Fonseca BD, Ciotti GE, Al-Ashtal HA, Jia JJ, Niklaus MR, Blagden SP, Alain T, Berman AJ. La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs. *eLife*. 2017 Apr; 6 e24146

Li YA, Donmez N, Sahinalp C, Xie N, Wang YW, Xue H, Mo F, Beltran H, Gleave M, Wang YZ, Collins C, Dong XS. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. *European Urology*. 2017 Jan; 71 (1) 68-78

Lin D, Ettinger SL, Qu SF, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang YZ. Metabolic heterogeneity signature of primary treatment-naive prostate cancer. *Oncotarget*. 2017 Apr; 8 (16) 25928-25941

Luk ISU, Shrestha R, Xue H, Wang YW, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang YZ. BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. *Clinical Cancer Research*. 2017 Mar; 23 (6) 1542-1551

Mahamud O, So J, Chua MLK, Bristow RG. Y Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. *Current Problems in Cancer*. 2017 Jul-Aug; 41 (4) 265-272

Maluch I, Levesque C, Kwiatkowska A, Couture F, Ly K, Desjardins R, Neugebauer WA, Prahla A, Day R. Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4. *Journal of Medicinal Chemistry*. 2017 Apr; 60 (7) 2732-2744

Masvidal Laia, Hulea Laura, Furic Luc, Topisirovic Ivan, Larsson Ola. mTOR-sensitive translation: Cleared fog reveals more trees. *RNA Biology*. 2017 Feb; 42917

McGee SR, Tibiche C, Trifiro M, Wang E. Network Analysis Reveals A Signaling Regulatory Loop in PIK3CA-mutated Breast Cancer Predicting Survival Outcome. *Genomics Proteomics & Bioinformatics*. 2017 Apr; 15 (2) 121-129

Meng F, Saxena S, Liu Y, Joshi B, Wong TH, Shankar J, Foster LJ, Bernatchez P, Nabi IR. The phospho-caveolin-1 scaffolding domain dampens force fluctuations in focal adhesions and promotes cancer cell migration. *Molecular Biology of the Cell*. 2017 Aug; 28 (16) 2190-2201

Nabavi N, Saidy NRN, Venalainen E, Haegert A, Parolia A, Xue H, Wang YW, Wu R, Dong X, Collins C, Crea F, Wang YZ. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. *Scientific Reports*. 2017 Jun; 7 4079

Nash C, Boufaied N, Mills IG, Franco OE, Hayward SW, Thomson AA.. Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts. *Molecular and Cellular Endocrinology*. 2017 May

Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. *Oncotarget*. 2017 Mar; 8 (12) 18949-18967

Olkhov-Mitsel E, Siadat F, Kron K, Liu LY, Savio AJ, Trachtenberg J, Fleshner N, Van der Kwast T, Bapat B. Distinct DNA methylation alterations are associated with cribiform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. *Oncology letters*. 2017 July; 14 (1) 390-396

Paproski RJ, Jovel J, Wong GKS, Lewis JD, Zemp RJ. Enhanced detection of cancer biomarkers in blood-borne extracellular vesicles using nanodroplets and focused ultrasound. *Cancer Research*. 2017 Jan; 77 (1) 3-13

Park NI, Guilhamon P, Desai K, McAdam RF, Langille E, O'Connor M, Lan XY, Whetstone H, Coutinho FJ, Vanner RJ, Ling E, Prinos P, Lee L, Selvadurai H, Atwal G, Kushida M, Clarke ID, Voisin V, Cusimano MD, Bernstein M, Das S, Bader G, Arrowsmith CH, Angers S, Huang X, Lupien M, Dirks PB. ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. *Cell Stem Cell*. 2017 Aug; 21 (2) 209

Patel PG, Selvarajah S, Guerard KP, Bartlett JMS, Lapointe J, Berman DM, Okello JBA, Park PC. Reliability and performance of commercial RNA and DNA extraction methods for FFPE tissue cores.

PLoS One. 2017 Jun; 12 e0179732

Rocha Joice, Aprikian Armen G, Vanhuysse Marie, Cury Fabio L, Hu Jason, Prévost Noémie, Dragomir Alice. Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. *CMAJ open*. 2017 5 (1) E265-E272

Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. *Br J Cancer*. 2017 Mar; 116 (6) 775-784

Seiler R, Oo HZ, Tortora D, Clausen TM, Wanga CK, Kumar G, Pereira MA, Orum-Madsen MS, Agerbk MO, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhofer T, Esfandnia S, Battsoqt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M. An oncofetal glycosaminoglycan modification provides therapeutic access to cisplatin-resistant bladder cancer. *European Urology*. 2017 July; 72 (1) 142-150

Shafer MER, Nguyen AHT, Tremblay M, Viala S, Beland M, Bertos NR, Park M, Bouchard M. Lineage Specification from Prostate Progenitor Cells Requires Gata3-Dependent Mitotic Spindle Orientation. *Stem Cell Reports*. 2017 Apr; 8 (4) 1018-1031

Sharma R, Shafer MER, Bareke E, Tremblay M, Majewski J, Bouchard M. Bmp signaling maintains a mesoderm progenitor cell state in the mouse tailbud. *Development*. 2017 Aug; 144 (16) 2982-2993

Sheeran PS, Matsuura N, Borden MA, Williams R, Matsunaga TO, Burns PN, Dayton PA. Methods of Generating Submicrometer Phase-Shift Perfluorocarbon Droplets for Applications in Medical Ultrasonography. *IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL*. 2017 Jan; 64 (1) 252-263

Singhal S, Jamaluddin MF, Lee E, Sloboda RS, Parliament M, Usmani N. Clinical factors and dosimetry associated with the development of prostate brachytherapy-related urethral strictures: A matched case-control study. *Brachytherapy*. 2017 Jul-Aug; 16 (4) 797-805

Tan Q, Joshua AM, Wang M, Bristow RG, Wouters BG, Allen CJ, Tannock IF. Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. *Cancer Chemotherapy and Pharmacology*. 2017 May; 79 (5) 959-969

Taylor RA, Fraser M, Livingstone J, Espiritu SMG, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. *Nature Communications*. 2017 Jan; 8 13671

Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A. Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Oncogene. 2017 July; 36 (28) 3964-3975

Vahid S, Thaper D, Zoubeidi A. Chaperoning the cancer: The proteostatic functions of the heat shock proteins in cancer. *Recent Patents on Anti-Cancer Drug Discovery*. 2017 12 (1) 35-47

Villalobos-Hernandez A, Bobbala D, Kandhi R, Khan MGM, Mayhue M, Dubois CM, Ferbeyre G, Saucier C, Ramanathan S, Ilangumaran S. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma. *Prostate Cancer and Prostatic Diseases*. 2017 Mar; 20 (1) 36-47

Wyatt A, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer T, Alumkal J, Thomas G, Reiter R, Rettig M, Evans C, Gao A, Chi K, Small E, Gleave M. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. *Journal of the National Cancer Institute*. 2017 Dec; 109 (12)

Zhang ZX, Lau J, Kuo HT, Zhang CC, Colpo N, Benard F, Lin KS. Synthesis and evaluation of F-18 -labeled CJ-042794 for imaging prostanoid EP4 receptor expression in cancer with positron emission tomography. *Bioorganic & Medicinal Chemistry Letters*. 2017 May; 27 (10) 2094-2098